Legal access to medications: a threat to Brazil's public health system?

被引:26
作者
Chieffi, Ana Luiza [1 ]
Barata Barradas, Rita De Cassia [2 ]
Golbaum, Moises [3 ]
机构
[1] Univ Sao Paulo, Fac Med, Prevent Med Dept, Ave Dr Arnaldo,455-2nd Floor Room 2168, BR-01246903 Sao Paulo, Brazil
[2] Santa Casa Sao Paulo Sch Med Sci, Researcher Natl Council Sci & Technol Dev CNPq 1C, Sao Paulo, Brazil
[3] Univ Sao Paulo, Prevent Med Dept, Fac Med, Researcher Natl Council Sci & Technol Dev CNPq 1C, Sao Paulo, Brazil
关键词
Judicialization of health; Universal Health System; Right to health; Pharmaceutical assistance; MEDICINES; JUDICIALIZATION; LAWSUITS; STATE;
D O I
10.1186/s12913-017-2430-x
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: In Brazil, health is fundamental human right guaranteed by the Constitution of 1988, which created the Brazilian Universal Health System (Sistema Unico de Saude - SUS). The SUS provides medications for outpatient care via policy of pharmaceutical assistance (PA) programmes. Despite the advances in PA policies which include the improvement in access to medications, there has been a significant increase in lawsuits related to health products and services. This study aimed to characterize the medication processes filed between 2010 and 2014 against the Secretary of State for Health of Sao Paulo (State Health Department of Sao Paulo - SES/SP), in Brazil, following PA policies. Methods: This descriptive study used secondary data on medication lawsuits filed against the SES/SP between 2010 and 2014. The data source was the S-Codes computerized system. Results: In the period evaluated, the number of lawsuits filed concerning health-related products increased approximately 63%; requests for medications were predominant. Approximately 30% of the medications involved in court proceedings were supplied via PA programmes. With regard to medications supplied via specialized component, 81.3% were prescribed in disagreement with the protocols published by the Ministry of Health. Insulin glargine was the most requested medication (6.3%), followed by insulin aspart (3.3%). Because there is no scientific evidence that either of these medicines is superior for the treatment of diabetes, neither of them has been incorporated into the SUS by the National Commission for Technology Incorporation. The judicial data showed that most of the lawsuits involved normal proceedings (i.e., individual demands), were filed by private lawyers, and named the State of Sao Paulo as the sole defendant, demonstrating the individual nature of these claims. The data indicate inequality in the distribution between the number of cases and lawyers and the number of lawsuits and prescribers, evidencing the concentration of lawyers and physicians in filing lawsuits. Conclusion: The judicialization of health in the State of Sao Paulo with the characteristics presented herein is a threat to the SUS.
引用
收藏
页数:12
相关论文
共 29 条
[1]   The principles of universality and integrality of the Brazilian National Public Health System from the perspective of the policy for rare diseases and the incorporation of technological resources [J].
Aith, Fernando ;
Bujdoso, Yasmim ;
Do Nascimento, Paulo Roberto ;
Dallari, Sueli Gandolfi .
REVISTA DE DIREITO SANITARIO-JOURNAL OF HEALTH LAW, 2014, 15 (01) :10-39
[2]  
Brasil, 1988, CONGRESSO NACL BRASI
[3]  
Brasil. Ministerio da Saude. Secretaria de Ciencia Tecnologia e Insumos Estrategicos, 2013, INS AN DIAB MELL TIP
[4]   Access to medium and high-complexity procedures in the Brazilian Unified National Health System: a matter of judicialization [J].
Castro Gomes, Fernanda de Freitas ;
Cherchiglia, Mariangela Leal ;
Machado, Carlos Dalton ;
dos Santos, Viviane Cristina ;
Acurcio, Francisco de Assis ;
Gurgel Andrade, Eli Iola .
CADERNOS DE SAUDE PUBLICA, 2014, 30 (01) :31-43
[5]   "Judicialization" of public health policy for distribution of medicines [J].
Chieffi, Ana Luiza ;
Barata, Rita Barradas .
CADERNOS DE SAUDE PUBLICA, 2009, 25 (08) :1839-1849
[6]  
D'Espíndula Thereza Cristina de Arruda Salomé, 2013, Rev. Bioét., V21, P438
[7]  
Machado MAD, 2011, REV SAUDE PUBL, V45, P590, DOI 10.1590/S0034-89102011005000015
[8]  
Carvalho José Alberto Magno de, 2003, Cad. Saúde Pública, V19, P725, DOI 10.1590/S0102-311X2003000300005
[9]  
Departamento de Assistencia Farmaceutica e Insumos Estrategicos, 2013, REL NAC MED ESS REN
[10]  
Departamento de Assistencia Farmaceutica e Insumos Estrategicos Secretaria de Ciencia Tecnologia e Insumos Estrategicos Ministerio da Saude, 2014, COMP ESP ASS FARM IN